美国 · SEC FORM 4
AIM ImmunoTech Inc.
AIM · NYSE · CIK 0000946644 · Healthcare · Biotechnology
内部人信号
1 位买方 · 4 条买入交易行 · $13.5K 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
- ⚠ Purchase size is modest relative to the model scale
- ⚠ 角色得分低 · 买入者中职位最高的是：CEO & President（CEO、董事长和持股 10% 以上的股东得分最低）
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: CEO & President. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 38.5
- 38.5
- 38.3
- 38.2
- 38.0
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -20.7%
- 3M
- -37.1%
- 6M
- -66.8%
- 12M
- -92.9%
波动率与流动性
- 波动率
- 189.7%
- Beta
- 1.27
- 平均每日成交额
- USD 858,134
估值
- 市值
- USD 7.3M
- P/E
- —
基本面
- 利润率
- 0.0%
- ROE
- -2382.3%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-06 · 价格来源：OpenBB/yfinance · 来自 Yahoo Finance：市值, 利润率, ROE · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 1,407,198
- 上期报告
- 2,765,187
- 日均成交量
- 1,866,131
- 回补天数
- ≤ 1.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | Equels Thomas K | 买入 (P) | Common Stock | 24,000 | USD 0.21 | USD 5,040 | SEC 申报 ↗ |
| 2026-09-16 | Equels Thomas K | 买入 (P) | Common Stock | 11,000 | USD 0.21 | USD 2,310 | SEC 申报 ↗ |
| 2026-09-15 | Equels Thomas K | 买入 (P) | Common Stock | 22,000 | USD 0.22 | USD 4,840 | SEC 申报 ↗ |
| 2026-09-14 | Equels Thomas K | 买入 (P) | Common Stock | 5,900 | USD 0.22 | USD 1,298 | SEC 申报 ↗ |
| 2025-06-13 | Equels Thomas K | 买入 (P) | Common Stock | 107 | USD 7.70 | USD 824 | SEC 申报 ↗ |
| 2025-06-12 | Equels Thomas K | 买入 (P) | Common Stock | 103 | USD 8.70 | USD 896 | SEC 申报 ↗ |
| 2025-04-11 | MITCHELL WILLIAM M | 买入 (P) | Common Stock | 196,851 | USD 0.03 | USD 5,906 | SEC 申报 ↗ |
| 2025-04-11 | KELLNER TED D | 买入 (P) | Common Stock | 1,968,504 | USD 0.03 | USD 59,055 | SEC 申报 ↗ |
| 2025-04-11 | Equels Thomas K | 买入 (P) | Common Stock | 1,968,504 | USD 0.03 | USD 59,055 | SEC 申报 ↗ |
| 2025-04-04 | Equels Thomas K | 买入 (P) | Common Stock | 41,000 | USD 0.06 | USD 2,460 | SEC 申报 ↗ |
| 2025-04-04 | Rodino Peter W III | 买入 (P) | Common Stock | 500 | USD 0.09 | USD 45 | SEC 申报 ↗ |
| 2025-03-05 | Equels Thomas K | 买入 (P) | Common Stock | 50,000 | USD 0.13 | USD 6,500 | SEC 申报 ↗ |
| 2025-03-04 | Equels Thomas K | 买入 (P) | Common Stock | 44,000 | USD 0.12 | USD 5,280 | SEC 申报 ↗ |
| 2025-03-04 | Equels Thomas K | 买入 (P) | Common Stock | 83,334 | USD 0.12 | USD 10,000 | SEC 申报 ↗ |
| 2024-12-18 | Equels Thomas K | 买入 (P) | Common Stock | 22,727 | USD 0.21 | USD 4,773 | SEC 申报 ↗ |
Form 4 申报证据
7 transaction lines in the latest 365-day window; 87 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | Equels Thomas K | 买入 (P) | Common Stock | 24,000 | USD 0.21 | USD 5,040 | SEC 申报 ↗ |
| 2026-09-16 | Equels Thomas K | 买入 (P) | Common Stock | 11,000 | USD 0.21 | USD 2,310 | SEC 申报 ↗ |
| 2026-09-15 | Equels Thomas K | 买入 (P) | Common Stock | 22,000 | USD 0.22 | USD 4,840 | SEC 申报 ↗ |
展开近期 Form 4 证据 (7 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | Equels Thomas K | 买入 (P) | Common Stock | 24,000 | USD 0.21 | USD 5,040 | SEC 申报 ↗ |
| 2026-09-16 | Equels Thomas K | 买入 (P) | Common Stock | 11,000 | USD 0.21 | USD 2,310 | SEC 申报 ↗ |
| 2026-09-15 | Equels Thomas K | 买入 (P) | Common Stock | 22,000 | USD 0.22 | USD 4,840 | SEC 申报 ↗ |
| 2026-09-14 | Equels Thomas K | 买入 (P) | Common Stock | 5,900 | USD 0.22 | USD 1,298 | SEC 申报 ↗ |
| 2026-03-12 | Equels Thomas K | C (C) | Common stock | 25,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-12 | CHEMEROW DAVID I. | C (C) | Common Stock | 25,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-05 | CHEMEROW DAVID I. | 奖励／授予 (A) | Common Stock | 2,800 | USD 1.23 | USD 3,444 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | AIM |
| CIK | 0000946644 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | NYSE |
数据覆盖
| 本地 Form 4 历史 | 87 transaction lines from 2020-08-21 to 2026-09-17 43 P purchase lines · 1 S sale lines · 43 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.